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Summary. On-demand therapy with recombinant acti-
vated factor VII (rFVIIa) can provide effective haemo-
stasis for spontaneous bleeds in haemophilia patients
with inhibitors. However, treatment approaches vary
amongst physicians, positively or negatively affecting
outcomes. A panel of physicians proposed recommen-
dations for securing and maintaining predictable
efficacy with rFVIIa, comparing these with ‘real-life’
patient management, using a questionnaire circulated to
other expert physicians from haemophilia care centres
in Europe and the United States. For rFVIIa treatment of
spontaneous bleeds in inhibitor patients, early interven-
tion with the highest appropriate dose is recommended.
Home-based therapy can facilitate early intervention. If
additional rFVIIa therapy is required after the initial
dose, rFVIIa 90 lg kg)1 may be administered at 2–3 h
intervals. Treatment should be tailored to bleed site/
severity, recognizing the advantages of appropriate
adjunct therapy. Questionnaire results suggested that
many respondents adopted strategies in line with the
recommendations. Most (36/46) recommended initial
therapy within 1 h of bleed onset. rFVIIa 270 lg kg)1
was the most frequently prescribed/recommended initial
dose for paediatric (aged £15 years; 22/44 respondents)
and adult (aged >15 years; 23/44 respondents) patients.
However, there may be opportunity for improved bleed
management on occasion, with regard, for instance, to
dosing and dose interval. To secure and maintain
predictable efficacy with rFVIIa, judicious dose selec-
tion and treatment timing are important, together with
adjunct therapy where necessary. As inhibitor patients
present with different bleeding scenarios, a tailored
treatment approach should be adopted.
Keywords: haemophilia, inhibitor, recombinant activated
factor VII, treatment strategies
Introduction
Recommendations for appropriate treatment of patients
with haemophilia A or B who have inhibitors to factors
VIII or IX, respectively, have been described in a
range of articles [1–8]. Recombinant activated factor
VII (rFVIIa, NovoSeven; Novo Nordisk, Bagsværd,
Denmark) is available for the treatment of bleeding in
such patients, and data have shown rFVIIa 90 lg kg)1
to provide effective haemostasis in over 90% of mild to
moderate bleeds after a mean of 2.2 injections [9].
Results from recent clinical trials [10–12] suggest that,
for on-demand treatment of haemarthroses in haemo-
philia patients with inhibitors, rFVIIa 270 lg kg)1
administered as one injection is as effective as the
repeat standard-dose regimen of 3 · 90 lg kg)1. In
2007, rFVIIa given as a single bolus dose of 270 lg kg)1
was approved by the European Medicines Agency for
treatment of mild to moderate bleeding episodes in
patients with haemophilia A or B and inhibitors.
Although articles reviewing the use of rFVIIa in hae-
mophilia patients with inhibitors are available [13–15],
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practical strategies for securing and maintaining pre-
dictable efficacy with rFVIIa remain to be fully
described in the literature. The development of
improved treatment protocols for haemophilia pa-
tients with inhibitors has been described as ‘impera-
tive’ [16]. Appropriate therapeutic recommendations
are important from a clinical point of view, as
treatment approaches can vary [17–22], with positive
or negative effects on treatment outcome, and from
an economic perspective [23], to ensure that maxi-
mum benefits are gained from the cost of administer-
ing the treatment.
In the light of the fact that treatment approaches can
be varied to optimize outcomes [17–22], this article
describes strategies for securing and maintaining pre-
dictable efficacy with on-demand rFVIIa treatment of
haemophilia patients with inhibitors, based on recom-
mendations from an expert group. These recommenda-
tions are compared with approaches adopted by other
physicians, elucidated from responses to an interna-
tional cross-sectional survey.
Methods
A panel meeting, held to consider strategies for
securing and maintaining predictable efficacy with
rFVIIa, was convened on 6th December 2008 in San
Francisco (CA, USA). Based on discussions that took
place during this meeting, recommendations relating to
the role of rFVIIa in the management of spontaneous
bleeds in haemophilia patients with inhibitors were
proposed.
To obtain further insight into bleed management with
rFVIIa in other haemophilia care centres, a question-
naire was devised (Appendix S1). This was sent via
e-mail to 115 physicians in Europe and the United
States who were known to prescribe rFVIIa to treat
patients with haemophilia and inhibitors. Thirty-seven
questionnaires were returned by October 2009. In
addition, 10 questionnaires were completed at an
investigators’ meeting that involved physicians from
Africa, Australia and Central and South America, as
well as from Europe.
Data from the 47 questionnaires were evaluated using
Analyse-it for Excel v2.21 (Analyse-it Software Ltd,
Leeds, UK). Summary statistics were produced (num-
bers of responses and percentages) and, where respon-
dents had been asked to estimate percentages of
instances/patients, mean [95% confidence interval
(CI)] results were determined (with the normality of
the data being assessed using measures of skewness,
kurtosis and the Shapiro–Wilk test). The number of
respondents and the percentage this represents, based
on a denominator, that varied with the total number of
correctly completed questionnaires, is provided for each
of the particular options. Additional written comments
provided by the respondents were collated.
Results
The recommendations of the authors of the manuscript
are given below and summarized in Table 1. Therapeu-
tic approaches reported by the questionnaire respon-
dents are also described.
Dose
For treatment-naı¨ve children (and bearing in mind
higher drug clearance rates in these younger patients
[24]), the recommended option is to initiate therapy
at 270 lg kg)1, and then consider subsequent dose
decreases. For treatment-naı¨ve adults, it is recommended
that therapy is initiated at 90 lg kg)1, with subsequent
dose escalation being considered. For initial treatment of
individuals at cardiovascular risk, rFVIIa 90 lg kg)1
may be prescribed – although the risk of thrombosis is
not generally a concern, this might be an issue in patients
with predisposing risk factors (e.g. elderly patients with
Table 1. Key recommendations for securing and maintaining predictable
efficacy with rFVIIa in on-demand treatment of haemophilia patients with
inhibitors.
Initial treatment
• Previously treated patients: highest appropriate rFVIIa dose*
• Treatment-naı¨ve children: rFVIIa 270 lg kg)1 with dose decrease
considered. Treatment-naı¨ve adults: rFVIIa 90 lg kg)1 with dose
increase considered
• Dose may be tailored according to bleed site (for target joints, muscles
and mucocutaneous bleeds), previous response to rFVIIa, any
cardiovascular risk factors and/or data from clotting assays assessing
ex vivo clot formation
• rFVIIa should ideally be administered within 1 h of bleed onset –
consider home-based treatment for suitable patients
Other treatment
• Rest, ice, compression, elevation (as appropriate)
• Consider adjunct therapy
n Antifibrinolytic treatment (joint, muscle and mucocutaneous bleeds)
n Steroids (joint and muscle bleeds)
n Physiotherapy (joint and major muscle bleeds)
Evaluation of bleed cessation
• Reduced pain, less heat, improved mobility as signs of improvement
Further therapy as appropriate
• rFVIIa 90 lg kg)1 with a 2–3 h time interval between doses
For difficult-to-treat bleeds
• Ensure the rFVIIa dose and dosing interval is appropriate, considering
dose escalation/dose interval reduction, if appropriate, to ensure
predictable efficacy
• Enquire about recent diet/homeopathic therapy/use of other drugs that
may affect haemostasis
• Consider further evaluations (other coagulation disorders, platelet
function etc.)
Possible hospitalization
• For management of severe or abnormal bleeds
• To facilitate treatment and treatment monitoring
• For patients with special problems
n To facilitate repeat dosing and physiotherapy
Rehabilitation
• To include coordinated/systematic physiotherapy, as appropriate
(including for muscle bleeds)
*Literature supporting high dose includes: Kavakli et al. [10], Santagostino
et al. [11], Young et al. [12], Salaj et al. [20], Abshire et al. [21].
Literature supporting early intervention includes: Lusher [17–19], Salaj
et al. [20], Santagostino et al. [22].
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atherosclerosis, obesity, etc.) if underlying disease is
exposed when improving coagulation.
Reassessment of response to rFVIIa after four to five
bleeding episodes will provide information to help
determine whether the treatment strategy is optimal or
requires modification. Continuous critical evaluation of
a patient’s history of efficacy can help to determine the
choice of initial dose of rFVIIa (90 vs. 270 lg kg)1), and
efficacy may be optimized by prescribing the highest
appropriate initial dose based on previous response
history.
If further rFVIIa therapy is required, rFVIIa
90 lg kg)1 may be administered at 2–3 h intervals.
Considering the questionnaire responses, an initial
dose of rFVIIa 270 lg kg)1 was the most frequently
prescribed/recommended regimen for paediatric (£15
years of age) and adult (>15 years of age) patients
(Fig. 1). If further treatment was required, for both age
groups, rFVIIa 90 lg kg)1 was most frequently reported
(Fig. 2), with 2- or 3-h time intervals between doses
being described most often (Fig. 3). However, more
than one-quarter of respondents mentioned using dos-
ing intervals greater than 3 h (Fig. 3).
Timing
An initial dose of rFVIIa should be administered as soon
as possible after bleeding starts, ideally within 1 h. It is
important that bleeds are recognized, and treated, early;
patients should be aware of this.
Most questionnaire respondents recommended that
patients receive initial rFVIIa therapy within 1 (36/46;
78.3%) or 2 h (9/46; 19.6%) of bleed onset, with only
one respondent recommending treatment initiation
within 3 h (1/46; 2.2%). In practice, a mean of 64.6%
(95% CI, 56.4–72.8) of bleeds were treated within
1–2 h. Recommendations for bleed recognition or
information on when and how to treat, were generally
considered useful for inhibitor patients, but only around
half the respondents (24/47; 51.1%) provided educa-
tional material to patients/caregivers.
Type and site of bleed
Although all joint bleeds should be treated comprehen-
sively, with appropriate follow-up and critical
evaluation of bleed cessation, treating haemarthroses
in target joints can be particularly challenging. In such
instances, rFVIIa 270 lg kg)1 may be appropriate
(although this dose has only been approved for mild
to moderate bleeding episodes, based on non-inferiority
studies). Adjunct therapy can include antifibrinolytic
treatment [25]. Steroids and physiotherapy may also be
Fig. 1. Questionnaire results: treatment of spontaneous bleeds in paediatric
(aged £15 years) and adult (aged >15 years) haemophilia patients with
inhibitors: rFVIIa doses administered as first-line therapy (the numbers shown
above the bars give the number of responses/number of respondents).
Fig. 2. Questionnaire results: treatment of spontaneous bleeds in paediatric
(aged £15 years) and adult (aged >15 years) haemophilia patients with
inhibitors: rFVIIa doses administered if further therapy is required (the
numbers shown above the bars give the number of responses/number of
respondents).
Fig. 3. Questionnaire results: treatment of spontaneous bleeds in paediatric
(aged £15 years) and adult (aged >15 years) haemophilia patients with
inhibitors: time intervalbetween rFVIIadoses if further therapy is required (the
numbers shown above the bars give the number of responses/number of
respondents).
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considered. No standard evidence-based strategy for
managing target joints has been established.
Large intramuscular bleeds should receive aggressive
therapy. Adjunct therapy can include antifibrinolytic
treatment and steroids. Even in non-haemophilic
athletes, repair and rehabilitation following muscle
injury may take more than 30 days [26], and thus
optimized treatment regimens require optimized mea-
sures for assessing ongoing bleeding/achieved haemo-
stasis [27].
For mucocutaneous bleeding, rFVIIa and/or antifi-
brinolytic therapy may be used. Skin bleeds do not
always require factor therapy, and cuts may be treated
using local compression. For bleeds in the oral cavity
and epistaxis, local measures (e.g. treatment in the oral
cavity/nasal passage) may be appropriate.
Both physiotherapy and RICE (rest, ice, compression,
elevation) may prove valuable options for bleed man-
agement, particularly for muscle bleeds. The nature of
any injury, together with its anatomical localization and
severity will dictate the type and intensity of physio-
therapy, influencing the progression of the rehabilita-
tion programme [26].
In line with the recommendations, the majority of
questionnaire respondents altered the therapy they
would normally employ when patients experienced
haemorrhages affecting target joints (27/47; 57.4%) –
when rFVIIa doses were described, the most frequently
reported dose was 270 lg kg)1 (Table 2). If further
rFVIIa treatment was required, a dose interval of 2 or
3 h was mentioned most often (Table 2); adjunct
therapy was also widely reported (Table 2). Fewer
respondents adjusted therapy for bleeds affecting non-
target (19/45; 42.2%) or weight-bearing joints (20/46;
43.5%).
Most respondents altered therapy for muscle bleeds
(29/47; 61.7%; Table 2). Around two-thirds (32/47;
68.1%) of respondents adjusted therapy for mucocuta-
neous bleeds, with adjunct treatment, particularly
antifibrinolytic therapy, often playing a role here
(Table 2).
The questionnaire respondents recommended physio-
therapy in a mean of 63.8% (95% CI, 55.5–72.1) of
patients, with the highest percentages recommended for
postsurgery patients [mean 86.3% (95% CI, 79.7–
92.9)] and for patients with target joints [mean 78.0%
(95% CI, 70.8–85.3)]. Overall, RICE was recom-
mended in a mean of 82.0% (95% CI, 73.8–90.1) of
patients.
Severe (difficult-to-treat) bleeds
Treatment options for ‘difficult-to-treat’ bleeds – those
with unusual persistence, or worsening of symptoms
despite therapy – vary according to circumstance, but
include further treatment with standard rFVIIa dosing,
dose increase (in patients not receiving rFVIIa
270 lg kg)1), shortening the dose interval, adjunct
antifibrinolytic therapy (except for haematuria) and
RICE. A recommended course of action may be to
initiate early contact with a hospital or treatment centre
to facilitate therapy with rFVIIa 270 lg kg)1, followed
by rFVIIa 90 lg kg)1 at 2-hourly intervals until the
bleed has resolved, together with appropriate protec-
tive/supportive physiotherapy and additional laboratory
monitoring.
Table 2. Treatments for bleeds at different sites and severe (difficult-to-treat) bleeds in haemophilia patients with inhibitors: questionnaire results showing
instances in which the majority of questionnaire respondents altered patients’ therapy*.
Anatomical localization/
type of bleed
Initial rFVIIa
dosage, lg kg)1
(%)
Dose interval
if further doses are
required, h (%)
Adjunct
therapy
(%)
Antifibrinolytics
(%)
Physiotherapy
(%)
Steroids
(%)
Target joint 270 (58) 1 (6) 93 43 60 40
120 (16) 2 (56)
90 (26) 3 (25)
6 (13)
Muscle bleeds 270 (47) 3 (35) 90 75 0 56
120–180 (13) 4 (44)
90 (39) 6 (24)
Mucocutaneous bleeds 270 · 1 (22) 1 (5) 96 100 0 0
120–150 · 1–2 (9) 2 (50)
90 · 1 (65) 3 (30)
4 (15)
Severe (difficult-to-treat) bleeds 270 · 1 (52) 2 (7) 95 78 78 6
120–150 (29) 3 (55)
90 (19) 4 (24)
6 (7)
12 (3)
*The percentages shown represent the percentages of responses where relevant information was given in relation to questioning: ‘Do you generally alter your
patient’s treatment (in various situations)’ and ‘If yes, how?’
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Patients who do not respond to therapy should be
fully assessed, and other causes of bleeding (e.g. other
coagulopathies, platelet dysfunction) should be con-
sidered. Laboratory/clinical evaluations can prove
informative, as might questioning patients about
recent use of other drugs, homeopathic therapy and
diet. Laboratory screening may include measurement
of prothrombin time and quantification of fibrinogen
levels. Thromboelastography [28] and thrombin-gen-
eration assays [29] are under consideration as
potential monitoring methods. Such assessments may
help to provide a mechanistic explanation of why
responses to rFVIIa may occasionally be attenuated in
patients who have previously responded well. In
instances of non-response, additional haemostatic
intervention, such as platelet transfusion or use of
other bypassing or prohaemostatic agents [30] could
be considered.
It is recommended that patients receive hospital-
based treatment for the management of all severe or
abnormal bleeds, including those that continue for more
than 24 h or worsen after initial home-based therapy
has been administered. Patients with special problems
(e.g. children who cannot receive treatment from their
parents, individuals with difficult venous access or cases
where therapeutic compliance may be suboptimal)
should also be treated in hospital. Inpatient admission
may also be recommended for bleeds in large joints or in
muscles.
The majority of questionnaire respondents (38/46;
82.6%) reported altering treatment in severe or diffi-
cult-to-treat bleeds. Over half (27/46; 58.7%) specifi-
cally highlighted rFVIIa dosing here, with the most
frequently reported dose and dose interval being
270 lg kg)1 and 3 h respectively (Table 2). When
managing difficult-to-treat bleeds, the rFVIIa dose
interval was reported to be reduced in a mean of
39.8% (95% CI, 29.3–50.2) of instances. Adjunct
therapy was also described (Table 2). This was most
often administered as antifibrinolytic treatment, but
other physicians mentioned use of steroids, or antifib-
rinolytics and steroids.
Most respondents asked patients to contact them or a
treatment centre if bleeds did not respond to 2–3 doses
of rFVIIa (32/47; 68.1%), as well as if bleeds were
severe (29/47; 61.7%) or abnormal (27/47; 57.4%).
Hospital admission for acute bleed management was
generally recommended in such instances.
When abnormal bleeding occurred, further evalua-
tion to try to ascertain the reason for this was performed
in a mean of 60.7% (95% CI, 49.8–71.5) of instances.
For patients who experienced unusual persistence or
worsening of symptoms, the majority of physicians (38/
47; 80.9%) considered it important to enquire about
recent diet/homeopathic therapy/use of other drugs.
Laboratory evaluations of other coagulation disorders
or platelet function in these circumstances were consid-
ered important by 30/47 (63.8%) and 24/47 (51.1%) of
respondents respectively.
Other points
Efforts should be made to ensure that patients and the
healthcare staff who treat them are adequately educated
about haemophilia with inhibitors – the term ‘pre-
habituation’ was introduced during the meeting, relat-
ing to guidance of patients, physicians and other
relevant healthcare staff to help secure and maintain
predictable efficacy with rFVIIa. The value of a multi-
disciplinary treatment approach should be recognized.
For many patients (having initially received hospital-
based treatment to foster appropriate expectation of
therapeutic response and provide guidance on bleed
evaluation), initiation of therapy at home should be
standard. This can facilitate prompt treatment, but close
contact should be maintained between patients and
clinics.
When evaluating bleed cessation, patients on home-
based treatment should be advised to look for decreased
pain, decreased heat and improved mobility. Patients
should visit clinics in any instances of doubt, acute lack
of response, severe pain, serious/persistent bleeds, or if
they suspect a bleed to be severe.
The questionnaire respondents exhibited widespread
agreement that having rFVIIa available at home aids
more rapid bleed resolution (46/47; 97.9%), and most
patients were estimated to have been trained and
regularly treated spontaneous bleeds at home [mean of
73.6% (95% CI, 65.1–82.0)]. The majority of respon-
dents considered home treatment to be suitable for
patients who have learned when/how to treat them-
selves, and when to seek further help (34/47; 72.3%),
for children whose parents/caregivers have such knowl-
edge (33/47; 70.2%), for compliant patients (28/47;
59.6%), and for patients who live in remote areas (28/
47; 59.6%). Most respondents (41/47; 87.2%) recom-
mended that their patients kept diaries so that progress
could be monitored and treatment optimized over time.
To signal bleed cessation, questionnaire respondents
most frequently reported asking patients to look for
improved mobility (42/47 responses; 89.4%) and
decreased pain (41/47; 87.2%). Decreased swelling
was also mentioned by a majority of respondents (36/
47; 76.6%), as was the bleeding site being less hot than
when bleeding began (24/47; 51.1%).
Discussion
For on-demand treatment of spontaneous bleeding in
inhibitor patients, efficacy may be optimized by pre-
scribing the highest appropriate dose of rFVIIa based on
a patient’s previous history of response (where
available). It may be speculated that initial treatment
with rFVIIa 270 lg kg)1 may be more beneficial than
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starting therapy with rFVIIa 90 lg kg)1 and subse-
quently increasing the dose and frequency. Such a
recommendation appears to be reflected in physicians’
current practice: for both paediatric and adult haemo-
philia patients with inhibitors, the most frequently
prescribed/recommended regimen reported by the ques-
tionnaire respondents was an initial dose of rFVIIa
270 lg kg)1. (In some instances, respondents men-
tioned rFVIIa doses in between the labelled 90 and
270 lg kg)1 doses.)
Consideration should be given to the convenience of
rFVIIa 270 lg kg)1. Compared with multiple venipunc-
ture, patients might prefer a treatment regimen involv-
ing fewer injections. Although some bleeds can be
treated with an rFVIIa dose lower than 270 lg kg)1,
most bleeds require more than one rFVIIa 90 lg kg)1
dose [9], and higher initial doses of rFVIIa do not
necessarily increase the amount of product required to
treat a bleed [11]. Indeed, it should be noted that recent
data have shown initial treatment with higher-dose
rFVIIa to be associated with a decline in total rFVIIa
consumption [20].
Data generated using in vitro models suggest that a
higher dose of rFVIIa may result in accelerated clot
formation and a stronger, more rapid thrombin burst on
the surface of activated platelets [21]. Increased and
rapid thrombin formation forms a tight fibrin plug with
greater resistance to fibrinolysis [31]. However, it
should be emphasized that management of haemophilia
involves more than a momentary correction of inade-
quate haemostasis; multiple bleeds can produce chronic
inflammatory reactions that need to be addressed, and
adjunct therapy may be important to consider.
Safety data have revealed a remarkably low incidence
of thromboembolic adverse events in patients treated
with rFVIIa, and no safety issues have been identified
relating to treatment of inhibitor patients with rFVIIa
270 lg kg)1 [32].
A first dose of rFVIIa should be administered as soon
as possible after bleeding starts, ideally within 1 h, and
data have shown that early treatment with rFVIIa is
associated with even greater efficacy and less product
use than later administration [17–20,22]. Although the
importance of early treatment was recognized by most
questionnaire respondents, responses also indicated that
in more than one-third of instances, bleeds may not be
treated within 2 h of onset. In relation to this, registry
data have shown that when patients are treated more
than 2 h after bleeds start, therapy with higher-dose
rFVIIa is associated with less re-bleeding [20].
Prompt receipt of a first dose of rFVIIa could be
facilitated by patients having the product immediately
available, with home-based treatment playing a key role
here. According to the questionnaire responses, a mean
of over 70% of patients were reported as regularly
treating spontaneous bleeds at home. However, when
considering a home-based treatment approach, it should
be recognized that some patients have limited skills,
which could preclude reliable self-administration of
rFVIIa, and there may also be issues relating to drug
availability for children in school.
We have recommended that patients on home-based
treatment should be advised to look for decreased pain,
decreased heat and improved mobility when evaluating
bleed cessation. The majority of questionnaire respon-
dents reported recommending these criteria. However,
around three-quarters also asked their patients to look
for decreased swelling – as it may take a considerable
period of time for swelling to subside, this may be less
useful.
When initial treatment with rFVIIa is followed by
further dosing, the time interval is important. Although
this was apparent in many of the questionnaire
responses, in some cases [including treatment of target
joint, muscle and severe (difficult-to-treat) bleeds], doses
were administered more than 3 h apart – such treatment
seems suboptimal, given the pharmacokinetic and
pharmacodynamic properties of rFVIIa [33].
Care in a haemophilia treatment centre is associated
with significantly reduced mortality [34]. Staff in these
centres can provide expert consultation and suitably
close monitoring during periods of haemostatic stress.
In addition, such centres may offer intensive patient
training, which can ultimately enable home therapy and
facilitate early treatment of bleeding episodes.
Some bleeds are difficult to treat; they continue with
unusual persistence or symptoms worsen despite treat-
ment. Current knowledge on the mechanism of action
of rFVIIa [35,36] may influence treatment strategy here:
high dose amplifies non-tissue factor dependent effects
and thrombin generation. Although not performed by
many of the questionnaire respondents, a full assess-
ment (including consideration of other causes of bleed-
ing) should be encouraged when bleeds prove difficult to
treat. Patients should be also asked about their exposure
to any factors that may influence haemostasis. For
instance, aspirin may affect blood clotting, whereas
other non-steroidal anti-inflammatory drugs, prescribed
for the treatment of chronic joint pain, can interfere
with platelet function, as might herbal compounds such
as willow bark or gingko biloba [37]. However,
evidence as to the influence that such effects may have
on rFVIIa therapy remains to be established.
Comparison of our recommendations with the ques-
tionnaire responses suggests that although physicians
may already adopt treatment strategies that are gener-
ally in line with rational recommendations, there may
be an opportunity for improved bleed management on
some occasions, with regard to, for instance, dosing and
dose interval, and assessing difficult-to-treat cases.
However, as inhibitor patients can present with differ-
ent bleeding scenarios, no single treatment strategy is
universally applicable, and clinical judgment will play a
key role in effective bleed management.
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When considering the recommendations described in
this document, it is important to refer to local regula-
tions specific for the country in which rFVIIa is being
prescribed. Also, inhibitor patients may receive immune
tolerance induction (ITI) therapy [38] and although our
recommendations provide general guidelines, ITI can
result in issues that are not specifically discussed in this
article (e.g. thrombosis may be associated with central
venous access devices [39]).
As we used a questionnaire to gain insight into bleed
management with rFVIIa in other clinics, it is appro-
priate to consider the limitations of this instrument. The
cross-sectional nature of the questionnaire was intended
to facilitate the collection of information in line with
each respondent’s expertise and available treatment
opportunities. However, selection bias in the physicians
to whom the questionnaire was sent, or in those who
responded, is possible. When respondents reported
altering treatment in certain situations, the precise
manner in which this was altered was not always
apparent. In addition, actions described in the ques-
tionnaire may not always have been adopted in clinical
practice. Nevertheless, the data collected provide valu-
able information about bleed management with rFVIIa
in clinical practice in a variety of countries.
Conclusion
These recommendations are intended to help physicians
secure and maintain predictable efficacy with rFVIIa
when treating spontaneous bleeds in haemophilia
patients with inhibitors. This can be achieved by
judicious treatment timing and dose selection together
with, where necessary, adjunct therapy – effective bleed
management involves more than a momentary correc-
tion of inadequate haemostasis. It may prove particu-
larly beneficial to explore such aspects of therapy in
bleeds that have proved difficult to treat. Early inter-
vention (which may be facilitated by home-based
therapy) with the highest appropriate dose of rFVIIa is
recommended.
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Supporting Information
Additional supporting information may be found
in the online version of this article:
Appendix S1. A ‘generic’ version of the ques-
tionnaire is shown. This was amended slightly for
distribution to physicians in different countries,
to comply with local regulations and drug licens-
ing arrangements.
Appendix S2. Physicians who provided ques-
tionnaire data, but did not participate in devising
the recommendations made in this manuscript.
Please note: Wiley-Blackwell are not respon-
sible for the content or functionality of any
supporting information supplied by the authors.
Any queries (other than missing material) should
be directed to the corresponding author for the
article.
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